AMGN vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 14, 2026

AMGN

39.1
AI Score
VS
MRNA Wins

MRNA

46.9
AI Score

Investment Advisor Scores

AMGN

Nov 14, 2026
39score
Recommendation
AVOID NEW MONEY

MRNA

Nov 14, 2026
47score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric AMGN MRNA Winner
Forward P/E 19.1571 23.0415 AMGN
PEG Ratio 2.8178 0 Tie
Revenue Growth 8.5% 29.2% MRNA
Earnings Growth 19.4% -85.1% AMGN
Tradestie Score 39.1/100 46.9/100 MRNA
Profit Margin 24.1% -110.5% AMGN
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation AVOID NEW MONEY HOLD Tie

Relative Price Performance (Last 90 Days)

AMGN 1M: +7.3% · 3M: +11.0% MRNA 1M: -5.6% · 3M: +246.5%

Current Technical Phase

AMGN

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.5% over 20 days), RSI 62

RSI (14): 61.8 · Price: $465.67

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 49.9 · Price: $223.37

Fundamentals Snapshot

Metric AMGN MRNA
Market Cap — —
Forward P/E 18.6 -51.5
Trailing P/E 27.1 —
Revenue (TTM) — —
Revenue Growth 0.1% 0.3%
Gross Margin 0.7% -0.4%
Operating Margin 0.3% -0.8%
EPS 17.25 -6.55
Dividend Yield 0.02% —

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.